Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;170(2):174-6.
doi: 10.1001/jamapediatrics.2015.3235.

Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab

Pascal M Lavoie  1 , Alfonso Solimano  2 , Richard Taylor  3 , Eddie Kwan  4 , Jennifer Claydon  5 , Stuart E Turvey  6 , Nico Marr  7
Affiliations

Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab

Pascal M Lavoie et al. JAMA Pediatr. 2016 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Lavoie reported receiving salary support from Child & Family Research Institute Clinician-Scientist and Michael Smith Foundation for Health Research (MSFHR) Career Investigator Awards. Dr Turvey reported holding the Aubrey J. Tingle Professorship in Pediatric Immunology and receiving a Clinical Research Scholar Award from the MSFHR. No other disclosures were reported.

Figures

Figure
Figure. Serum Respiratory Syncytial Virus (RSV) Neutralizing Antibody Titers in Infants in the Abbreviated Palivizumab Dosing Program
A subset of infants approved to receive either 3 or 4 doses of palivizumab were tested before any palivizumab dose, between 1 and 5 days after a first dose of palivizumab, and at the end of the RSV season (at least 30 days after the last palivizumab dose or after April 15, whichever came last). The RSV neutralizing antibody titers were also determined in season-matched healthy adults. The RSV neutralizing serum antibody titer equivalents (NT95) are based on the ability of a serum dilution (expressed as 1/titer) to inhibit 95%or more of viral infection. In this assay, we determined that palivizumab serum concentrations of 40 μg/mL correspond to a median neutralizing antibody titer of 1:12 (dotted line with minimum and maximum values [shaded area from 3 independent experiments performed in duplicate]). Detection limit was NT95 of approximately 4 (or 1/4), equivalent to a serum concentration of palivizumab of approximately 6.25 μg/mL except for predose serum samples for which the detection limit of the assay was NT95 of approximately 2. Error bars represent median with interquartile range.
See this image and copyright information in PMC

References

    1. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215–1224. - PubMed
    1. Brady MT American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–420. - PubMed
    1. Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015;169(4):341–348. - PMC - PubMed
    1. Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE. Reduced-dose schedule of prophylaxis based on local data provides near-optimal protection against respiratory syncytial virus. Clin Infect Dis. 2015;61(4):506–514. - PMC - PubMed
    1. Mitchell I, Paes BA, Li A, Lanctôt KL CARESS investigators. CARESS: the Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2011;30(8):651–655. - PubMed

Publication types

MeSH terms